Article thumbnail
Location of Repository

Candesartan in heart failure

By Toni L Ripley, Jennifer S Chonlahan and Robin E Germany

Abstract

Candesartan cilexetil is a nonpeptide selective blocker of the angiotensin II receptor sub-type 1. It is a prodrug that is converted to its active metabolite during its variable absorption. It is highly protein bound with a small volume of distribution and a nine-hour half-life. Candesartan is one of two angiotensin receptor blockers approved for use in heart failure. MEDLINE was searched using OVID and PubMed to evaluate the evidence for using candesartan in patients with heart failure. Pharmacologic and pharmacokinetic evaluations, as well as clinical trials, were selected and are presented in this review. Clinical evidence supports the indication for use in systolic heart failure. Results for use in patients with diastolic heart failure were non-significant. Candesartan was well tolerated in the trials, with hyperkalemia, renal dysfunction, and hypotension being the most common adverse events. Use of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors needs further study; however, candesartan appears to provide added benefit in this setting. Candesartan is a safe and effective option for patients with systolic heart failure. Data regarding other angiotensin receptor blockers is underway

Topics: Reviews
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2699637
Provided by: PubMed Central

Suggested articles

Citations

  1. (1997). Absorption, metabolism, and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers.
  2. (2003). Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. A Heart J,145:e14.
  3. (2003). Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. Am Heart J,
  4. (2002). Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department. Rev Cardiovasc Med,
  5. (2005). Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomized, controlled clinical trial.
  6. (2001). Aldosterone in congestive heart failure.
  7. (2003). Angiotensin AT2 receptors: cardiovascular hope or hype?
  8. (2003). Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease.
  9. (2001). Angiotensin II modulates catecholamine release into interstitial fl uid of canine myocardium in vivo.
  10. (1990). Angiotensin II-forming pathways in normal and failing human hearts. Circ Res,
  11. (1982). Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate effi cacy of converting enzyme blockade.
  12. (1997). Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil.
  13. (2004). Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system.
  14. (2003). Candesartan cilexetil in haemodialysis patients.
  15. (2006). Candesartan cilexetil, Atacand: Label revision,
  16. (2006). Candesartan cilexetil, Atacand®: clinical pharmacology and biopharmaceutics review [online].
  17. (1997). Candesartan cilexetil: a review of its preclinical pharmacology.
  18. (2002). Candesartan cilexetil: an update of its use in essential hypertension.
  19. (2005). College of Cardiology–American Heart Association.
  20. (1999). Comparison of candesartan, enalapril, and their combination in congestive heart failure: the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study.
  21. (1999). Contemporary management of patients with left ventricular systolic dysfunction: Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry.
  22. (2004). Effect of candesartan and verapamil on exercise tolerance in diastolic dysfunction.
  23. (2004). Effect of candesartan on causespecifi c mortality in heart failure patients:
  24. (2004). Effect of candesartan on New York Heart Association functional class:
  25. (1999). Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF).
  26. (2003). Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction.
  27. (2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-convertingenzyme inhibitors.
  28. (2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors.
  29. (2005). Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction.
  30. (1997). Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults.
  31. (2003). Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
  32. (2006). Executive Summary: HFSA
  33. (2006). Failure Society of America.
  34. (2006). Heart Association.
  35. (2003). Heart failure.
  36. (2000). Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients.
  37. (2000). Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
  38. (2000). Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev,
  39. (1995). Other cardiomyopathies. In:
  40. (1995). Overview of randomized trials of angiotensin-converting enzyme inhibitors on morbidity and mortality in heart failure.
  41. (1999). Pathophysiology of heart failure: a look at the future.
  42. (2004). Pathophysiology of heart failure.
  43. (1999). Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function.
  44. (1998). Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function.
  45. (1997). Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
  46. (1997). Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.
  47. (1997). Randomised trial of losartan versus captopril in patients over 65 with heart failure
  48. (2000). Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting-enzyme inhibitors.
  49. (2005). The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy.
  50. (2000). The cardiac rennin-angiotensin system: Novel signaling mechanisms related to cardiac growth and function. Regul Pept,
  51. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure.
  52. (2001). Tognoni G; for the Valsartan Heart Failure Study Group.
  53. (1996). US Carvedilol Heart Failure Study Group.
  54. (2003). Valsartan in Acute Myocardial Infarction Trial Investigators.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.